monoisoamyl-2,3-dimercaptosuccinate has been researched along with Chronic Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhadauria, S; Flora, SJ; Pachauri, V; Yadav, A | 1 |
| Flora, SJ; Modi, M | 1 |
2 other study(ies) available for monoisoamyl-2,3-dimercaptosuccinate and Chronic Disease
| Article | Year |
|---|---|
Monoisoamyl 2, 3-dimercaptosuccinic acid (MiADMSA) demonstrates higher efficacy by oral route in reversing arsenic toxicity: a pharmacokinetic approach.
Topics: Administration, Oral; Animals; Arsenic; Arsenic Poisoning; Chelating Agents; Chronic Disease; Copper; Dose-Response Relationship, Drug; Glutathione; Glutathione Disulfide; Kidney; Liver; Liver Function Tests; Male; Oxidative Stress; Rats; Rats, Wistar; Succimer; Zinc | 2012 |
Combined administration of iron and monoisoamyl-DMSA in the treatment of chronic arsenic intoxication in mice.
Topics: Animals; Arsenic; Arsenic Poisoning; Brain; Chronic Disease; Drug Therapy, Combination; Iron; Kidney; Liver; Male; Mice; Oxidative Stress; Succimer; Zinc | 2007 |